Coccidiosis, which is caused by obligate, intracellular, protozoan parasites belonging to several species of the genus Eimeria, is a major problem for the poultry industry. Currently, the disease, which is controlled by the use of prophylactic chemotherapy, costs the broiler chicken industry worldwide an estimated $250 million per annum (29) . Because of the expense of new drug development and the occurrence of drug-resistant parasites, an alternative method of disease control is desirable.
In recent years, modern approaches to vaccine development utilizing hybridoma and recombinant DNA technologies have been applied extensively to the problem of coccidiosis of the domestic chicken (6, 7, 10, 17) . However, the recombinant antigens isolated to date either have not been tested in vivo or have been disappointing in their ability to protect broilers against coccidiosis (2, 11, 12, 24, 31) . Nevertheless, the development of a subunit (recombinant) vaccine against coccidiosis for the broiler chicken industry still remains an attractive alternative to chemoprophylaxis.
Until recently, it was thought that a live coccidial infection was essential for an effective immune response to protect against a pathogenic challenge (37) . There are live coccidiosis vaccines available, such as Immunocox (26) and Coccivac (Sterwin Laboratories) , and others are under development for the broiler industry (27, 40) . However, recent results from our laboratory and others have shown that live infection is not mandatory for protection but that dead antigen such as a crude parasite extract can also protect against severe coccidiosis (32) . These would allow vaccine production by recombinant DNA technology.
In subsequent studies, the crude, protective parasite extract was subfractionated by S200 chromatography, and a protective fraction (fraction V) which contained several polypeptides with a limited molecular weight range was identified (23) . By using antisera raised against fraction V and against various other protective parasite extracts, a Agtll'cDNA library of Eimeria tenella was screened and clones representing the major polypeptides of fraction V were isolated (35) . By using immunopositive clones from the E. tenella cDNA library and a novel bacterial expression vector, CheY (18) , fusion proteins were engineered, expressed, purified, and tested for protective ability against coccidiosis with broilers in our battery model. Several recombinant proteins from five antigen classes (35) (21, 30) .
A crude antigen preparation was made from each of the strains by disrupting the oocysts fully by shaking them with glass beads (2-mm diameter) in Dulbecco's PBS (Ca2+ and Mg2+ free, pH 7.2) containing a cocktail of protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 mM 1,10-phenanthroline, 48 pLg of soybean trypsin inhibitor per ml, 48 jig of aprotinin per ml, 0.04 mM leupeptin, 13 mM benzamidine, and 5 mM EDTA). Low-speed centrifugation (700 x g, 10 min) pellets were obtained from each disrupted oocyst preparation and were solubilized by heating them to 100°C for 5 to 10 min in sample buffer (2% SDS, 5% ,-mercaptoethanol, 10% glycerol, and 0.003% bromophenol blue in 62.5 mM Tris hydrochloride [pH 6.8] ). Any particulate material was removed by centrifugation (13 ,000 x g, 5 min), and the protein content of the supernatant was determined by the modified Bradford method (38) . The solubilized polypeptides of the seven samples were resolved by SDS-PAGE by using a Protean I chamber (Bio-Rad Laboratories) according to the manufacturer's instructions, which are based on the method of Laemmli (25) . The samples, 50 ,ug of protein in sample buffer, were applied to a 10% polyacrylamide resolving gel with a 3% polyacrylamide stacking gel. Recombinant CheY-S07' (20 vig) and biotinylated SDS-PAGE molecular weight standards were also run in lanes adjacent to the oocyst samples. Following electrophoresis, the polypeptides were transferred to nitrocellulose (Hoefer Scientific Instruments) in a Transblot chamber (Bio-Rad Laboratories) according to the manufacturer's instructions, which are based on the method of Towbin et al. (41) . The B antigens were localized in the transferred polypeptides by using a double antibody method (1) utilizing a Bio-Rad Immuno-Blot assay kit. Following incubation with the first antibody, a hyperimmune rabbit anti-CheY-SO7' antiserum, the nitrocellulose sheet was incubated with the second antibody, a goat anti-rabbit immunoglobulin G (heavy and light)-alkaline phosphatase conjugate. B antigen localization was revealed with a color development substrate. The molecular weight standards were visualized by incubation with an avidin-alkaline phosphatase conjugate and then with the color development substrate (15) .
Solid-phase fluorescence immunoassay. To determine whether chicken sera contained specific antibodies to either recombinant CheY-SO7' or to whole sporulated oocyst antigen (SOA), a solid-phase fluorescence immunoassay was employed (44 
RESULTS
Expression and purification of the CheY-S07' fusion protein. Figure 1A shows schematically the construction of the recombinant plasmid. Following transformation of the E. coli host, colonies were picked and the orientation of the S07' insert with respect to the CheY portion of the operon was determined by restriction enzyme mapping of the plasmid from each clone. The clone CheY-S07'/9 had the correct orientation of S07' for the expression of a large fusion protein and was chosen for the purification of the recombinant antigen.
The fusion protein in the crude bacterial cell extract made from this clone, solubilized in guanidine HCl and urea, was applied to a hydroxyapatite column and was eluted with 10 and 20 mM sodium phosphate buffer washes. As shown in Fig. 1B , the clone CheY-S07'/9 expressed a fusion protein with the appropriate molecular mass of approximately 36 kDa and was defined as a recombinant antigen of the B class on the basis of its reactivity with specific antisera (34a). Note that analysis of corresponding fractions from a bacterial lysate derived from a clone containing the CheY expression vector with S07' inserted in the reverse orientation did not reveal a protein of the characteristic size or immunoreactivity. For experimental vaccinations, purified recombinant antigen preparations were stored in buffer containing 7 M urea (22) at -20°C until use.
In vivo protection. Since its identification, several batches of the recombinant B antigen CheY-S07' have been produced and purified and have shown consistent protection in broiler chicks against coccidiosis caused by E. tenella, E. acervulina, and E. maxima infection (8) . Over an extended period of time, several thousand broilers have been immunized with this antigen. The frequency distribution of lesion scores from large numbers of chicks provides a clear demonstration of the protective ability of CheY-S07' antigen. A comparison of the frequency distribution of lesion scores in immunized and nonimmunized broilers infected with E. tenella and E. maxima, pooled from several individual experiments involving several hundred chickens, is shown in Fig. 2A and B In addition to protecting broilers against severe coccidiosis caused by E. tenella, E. acervulina, and E. maxima, the recombinant B antigen CheY-S07' also protects broilers against E. necatrix-induced coccidiosis (Fig. 3) . The level infection (live vaccine groups), CheY-S07' immunization does not normally reduce the mean lesion score to below 1.5. As noted in Fig. 2 , there tend to be a few chicks which do not respond to CheY-S07' immunization and subsequently develop severe coccidiosis when challenged with a pathogenic dose of sporulated oocysts. In contrast, the experimental groups immunized by live infection usually show a much tighter distribution of lesion scores and, by using an appropriate dose, individual lesion scores can be reduced to 1.0 or less (data not shown). Increasing the dose of CheY-S07' from 1 ,ug to 10 jig (Fig. 3) or increasing the number of doses (8) does not improve the observed protection.
Western blot analysis. CheY-S07' antigen was obtained from a cDNA library of E. tenella and has been shown to be present in the sporulated oocyst, localized in the refractile body of the sporozoite (34a). It is interesting that unlike live vaccination, which is species-specific, CheY-S07' crossprotects against at least four species of chicken coccidia (Fig. 3) . Thus, to determine whether the B class of antigen is common to all species of chicken coccidia, immunoblots of SDS-PAGE-resolved polypeptides of sporulated oocysts of the seven species were undertaken. The localizing antibody preparation was a hyperimmune rabbit anti-CheY-S07' antiserum, and recombinant CheY-S07' antigen was used as the positive control. By using reactivity with the anti-CheY-S07' antiserum to define the B antigen class, all species of chicken coccidia were found to possess a predominant polypeptide band characteristic of B antigen (Fig. 4) . As determined by the mobility of the molecular weight markers, the antigens from the various species have molecular masses of approximately 26 to 28 kDa, as shown previously for E. tenella, E. acervulina, and E. maxima (33) . There is some interspecies variation in the relative mobilities of the B antigens, which may reflect differences in the molecular weight and/or other characteristics of the antigen between the different species of coccidia. As expected, the recombinant B antigen CheY-S07' has a higher molecular mass (approximately 36 kDa) because of the contribution of CheY in the fusion protein (22) .
Chicken antibody to recombinant CheY-S07'. It is known that eimerian sporozoites are very sensitive to the action of antibody and complement (5) and that chickens can be partially protected from coccidiosis by passive transfer of specific antibody (6, 36, 43) . To ascertain whether the CheY-S07' immunization of broiler chicks induced antibody production, serum samples were obtained from chicks which had undergone a variety of immunization regimens. Since the observed protection was induced by purified antigen without any adjuvant, no adjuvant was used in any of these immunizations.
Young chicks, less than 14 days old, which had not been immunized with CheY-S07' had demonstrable levels of antibody to both CheY-S07' and the crude parasite extract, SOA (Table 1) . Since these chicks were very young and were reared in isolation, it can be assumed that this reactivity is due to maternal antibody; sera from chicks older than two weeks of age did not demonstrate this reactivity. Immunization with CheY-S07' did not induce specific antibody in either young or older chicks. The only other chicks tested which demonstrated CheY-S07'-specific antibody in their sera were those hyperimmunized with whole sporozoite antigen in Freund's adjuvant and the much older chicks from breeder flocks which had been exposed to live coccidia for extended periods of time.
DISCUSSION
Problems incurred because of the emergence of drugresistant strains of Eimeria spp. and the difficulty in discovering and developing new anticoccidial agents have emphasized the need for novel approaches for the control of coccidiosis in the poultry industry (4). It is well established that infection with virulent (14, 42) or attenuated (20) ), E. aceriulina (_), E. maxima ( M ), and E. necatrix ( E). Groups (8 to 10 chicks per group) of 2-to 4-day-old chicks either were immunized with 1 jig (B-1 jug) or 10 jig (B-10 ,ug) of B (CheY-SO7') antigen per chick, were sham immunized with buffer (Buffer), were inoculated with an immunizing dose of sporulated oocysts equivalent to a live vaccine (L.V.), or were untreated (None). The live vaccine dose was 100 sporulated oocysts per chick for E. tenella, 2,000 sporulated oocysts per chick for E. acervulina, 50 sporulated oocysts per chick for E. maxima, and 1,000 sporulated oocysts per chick for E. necatrix. At approximately 3 weeks of age, the chicks were challenged with pathogenic doses of sporulated oocysts of one of the four species tested, and lesion scores were evaluated 6 days postinfection for E. acervulina and 7 days postinfection for E. tenella, E. maxima, and E. necatrix. The bars represent mean lesion scores; standard errors of the mean ranged between 0.08 and 0. 29. of coccidia induces strong, species-specific, protective immunity in chickens. Nevertheless, the use of available live vaccines consisting of virulent strains for the control of coccidiosis is not widespread but is limited mostly to chicken breeder flocks, suggesting that such vaccines are not suitable for broiler production. Attenuated live vaccines for the broiler industry are being developed (3, 16, 34) . However, as with other live vaccines, there are concerns about stability, quality control, cost-effectiveness, and efficacy against the vast array of field strains likely to be encountered in different geographical areas (4, 9) . The development of a subunit vaccine would circumvent some of these problems.
The recombinant antigen (CheY-S07') described here is remarkable in that it induces cross-protective immunity against at least four major species of coccidia and is effective at relatively low doses (8 could cross-protect against not only all chicken coccidia but also against other species. However, in contrast to live vaccination, B antigen, even at relatively high doses, does not induce sterile immunity nor does it fully prevent disease. These results indicate some fundamental differences between immunity induced by mild infection and that induced by the B antigen; it would appear that B antigen is not As expected with the low antigen doses used in the absence of any adjuvant, B antigen immunization did not elicit antibody production, indicating that cell-mediated mechanisms may be involved in the observed partial protection. However, it is interesting to note that chicks exposed to parasite antigens either through prolonged, natural exposure (as with breeder chicks) or by hyperimmunization do produce antibodies to B antigen. Since B antigen immunity is incomplete (that is, it provides partial protection only), either enhanced antigen presentation, such as with a viral vector, or the addition of other antigens should improve efficacy to a level at which such a vaccine (subunit) would be competitive with chemotherapy.
Contained within the sequence of S07' (28) and at its carboxy terminus is the sequence of another partially protective, recombinant antigen, GX3262 (31) . However, there are major differences between the abilities of the two antigens to immunize chicks against coccidiosis. In contrast to GX3262, a single low dose (10 ng) of CheY-S07' in the absence of any adjuvant is sufficient to protect 2-day-old chicks against severe coccidiosis caused by infection with any one of several species of coccidia for several weeks after immunization (8) . Whether this is due to the larger size of S07', providing more, important epitopes (at the amino terminus), or due to the fact that CheY-S07' is a CheY fusion protein (rather than a 3-galactosidase fusion protein) is under investigation. The ability to obtain CheY fusion protein with high purity (22) may also contribute to the low-dose efficacy (based on total protein per dose) of CheY-S07'. These differences also exist between CheY-S07' and other refractile body recombinant antigens (11) . Nevertheless, despite qualitative and quantitative differences, it is interesting that several protective antigens have been identified which originate in the refractile body of the parasite.
All of the studies reported here have been conducted in our cage model for chicken coccidiosis. In addition to studies aimed at improving the efficacy of the B antigen so that mean lesion scores would be reduced to below 1.0 in immunized chicks, other studies to demonstrate protection against coccidiosis, including productivity competitive with chemotherapy under floor-pen conditions, are ongoing.
